(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 August 2012 (16.08.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/107363 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 31/4174* (2006.01)
A61K 9/28 (2006.01) *A61K 31/427* (2006.01)
A61K 9/48 (2006.01) *A61K 31/437* (2006.01)
A61K 31/192 (2006.01) *A61K 31/44* (2006.01)
A61K 31/343 (2006.01) *A61K 31/444* (2006.01)
A61K 31/37 (2006.01) *A61K 31/472* (2006.01)
A61K 31/4015 (2006.01) *A61K 31/498* (2006.01)
A61K 31/404 (2006.01)

(21) International Application Number:
PCT/EP2012/051880

(22) International Filing Date:
3 February 2012 (03.02.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
11153541.5 7 February 2011 (07.02.2011) EP

(71) Applicant *(for all designated States except US)*: **SCIPHARM SÀRL** [LU/LU]; 33, rue Hiehl, L-6131 Junglinster (LU).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FREISSMUTH, Michael** [AT/AT]; Pharmakologisches Institut, Waehringer Str. 13a, A-1190 Wien (AT). **GLOECKEL, Christina** [AT/AT]; Pharmakologisches Institut, Waehringer Str. 13a, A-1090 Wien (AT). **KOENIG, Xaver** [AT/AT]; Pharmakologisches Institut, Waehringer Str. 13a, A-2340 Moedling (AT). **KEUERLEBER, Simon** [DE/AT]; Pharmakologisches Institut, Waehringer Str. 13a, A-1090 Wien (AT).

(74) Agents: **LOIDL, Manuela** et al.; Donau-City-Strasse 1, A-1220 Vienna (AT).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2012/107363 A1

(54) Title: NOVEL COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS

(57) Abstract: The present invention provides a composition comprising at least one prostacyclin or prostacyclin analogue or a pharmaceutically acceptable salt thereof and at least one phosphodiesterase (PDE) 4inhibitor and optionally a further PDE inhibitor for use in preventing or treating cystic fibrosis by selectively increasing the cAMP levels in bronchoepithelial cells.